(Reuters) - Japan's No.4 drug maker Eisai Co Ltd (4523.T) expects sales to stay slack over the next five years after the loss of U.S. patent protection for Aricept, its top-selling Alzheimer's drug, leading it to cut jobs.
via reuters.com
(Reuters) - Japan's No.4 drug maker Eisai Co Ltd (4523.T) expects sales to stay slack over the next five years after the loss of U.S. patent protection for Aricept, its top-selling Alzheimer's drug, leading it to cut jobs.
1 comment:
Post a Comment